Singapore Atrial Fibrillation Study (SAFS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02791022|
Recruitment Status : Recruiting
First Posted : June 6, 2016
Last Update Posted : June 6, 2016
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Device: SPYDER ECG sensor|
The implications of PAF detection in an individual are huge to the individual and the community as it increases the risk of embolic stroke and other embolic phenomenon. Once detected, intervention can be taken to lower such an individual's clinical risk and decrease the clinical burden to the community. The lack of suitable tools and large population cohorts has led to a likely underestimation of PAF in various patient populations. This study will specifically address and characterize the different incidence on PAF in various patient populations and hence help to target at risk groups for earlier screening and intervention.
Patients with HF are more likely than the general population to develop AF. Conversely AF is also a strong independent risk factor for subsequent development of HF.
In Heart Failure (HF) patients, later development of AF was associated with increased mortality. Preexisting HF adversely affected survival in individuals with AF. Both HF with reduced ejection fraction (HFrEF) and Heart Failure with a Preserved Ejection Fraction (HFpEF) patients are at greater risk for AF. There is a direct relationship between functional state (as shown by the NYHA class) and prevalence of AF in patients with HF progressing from 4% in those who are NYHA class I to 40% in those who are NYHA class IV.
Acute HF decompensation in patients with prior HF is due to AF as a precipitant in 5.4% of cases in a single center study.
Knowing the true prevalence of AF in HF will allow us to plan for strategies to further reduce the clinical burden of HF.
|Study Type :||Observational|
|Estimated Enrollment :||2500 participants|
|Official Title:||A Multi-centre Population-based Study on the Incidence of Paroxysmal Atrial Fibrillation in Inpatient and Outpatient Cohorts in Singapore|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||March 2019|
- Paroxysmal Atrial Fibrillation [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02791022
|Contact: Hanna Liawemail@example.com|
|National Heart Centre Singapore||Recruiting|
|Singapore, Singapore, 169609|
|Contact: Hanna Liaw 67042274 firstname.lastname@example.org|
|Principal Investigator: Chi Keong Ching|
|Principal Investigator:||Chi Keong Ching||Singhealth Foundation|